AVEO Pharmaceuticals (NASDAQ:AVEO) Sees Large Volume Increase After Strong Earnings

Share on StockTwits

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares saw an uptick in trading volume on Wednesday after the company announced better than expected quarterly earnings. 196,654 shares traded hands during trading, a decline of 95% from the previous session’s volume of 4,142,819 shares.The stock last traded at $0.63 and had previously closed at $0.56.

The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.09. AVEO Pharmaceuticals had a negative return on equity of 50.69% and a negative net margin of 46.69%. The business had revenue of $25.72 million for the quarter.

Several brokerages have recently issued reports on AVEO. HC Wainwright reaffirmed a “buy” rating and set a $1.75 price target on shares of AVEO Pharmaceuticals in a research note on Tuesday, October 1st. Piper Jaffray Companies cut their target price on AVEO Pharmaceuticals from $4.00 to $2.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. One analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $1.92.

A number of large investors have recently added to or reduced their stakes in AVEO. NEA Management Company LLC lifted its stake in AVEO Pharmaceuticals by 20.8% in the second quarter. NEA Management Company LLC now owns 25,243,865 shares of the biopharmaceutical company’s stock valued at $16,913,000 after buying an additional 4,347,827 shares during the period. Vanguard Group Inc. lifted its stake in AVEO Pharmaceuticals by 26.7% in the second quarter. Vanguard Group Inc. now owns 7,670,096 shares of the biopharmaceutical company’s stock valued at $5,164,000 after buying an additional 1,614,802 shares during the period. Paloma Partners Management Co acquired a new position in AVEO Pharmaceuticals in the second quarter valued at about $321,000. OZ Management LP acquired a new position in AVEO Pharmaceuticals in the second quarter valued at about $244,000. Finally, Morgan Stanley lifted its stake in AVEO Pharmaceuticals by 265.4% in the second quarter. Morgan Stanley now owns 399,742 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 290,354 shares during the period. 29.56% of the stock is currently owned by hedge funds and other institutional investors.

The firm has a 50 day simple moving average of $0.81 and a two-hundred day simple moving average of $0.76. The company has a debt-to-equity ratio of 6.84, a current ratio of 2.21 and a quick ratio of 2.21. The stock has a market cap of $81.98 million, a price-to-earnings ratio of -3.68 and a beta of 0.75.

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Recommended Story: What is the Coverage Ratio?

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.